Retrovirus News and Research

RSS

Patients with AIDS-related lymphomas may face increased risk of CNSi

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.

31 May 2014

20th International AIDS Conference calls for end to discrimination against HIV patients

A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.

16 May 2014

Nearly half of HIV-infected teenagers, young adults forego treatment

Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children's Center.

4 Feb 2014

EGPAF donates medical equipment to Swaziland to improve health of mothers and children

The Elizabeth Glaser Pediatric AIDS Foundation in collaboration with Project C.U.R.E (Commission on Urgent Relief and Equipment) today donated medical equipment and supplies worth more than U.S. $500,000 to the Government of the Kingdom of Swaziland's Ministry of Health to help strengthen health services provided to mothers, infants, and children in the country.

30 Jan 2014

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.

29 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs.

9 Jan 2014

Medicare seeks to tighten drug program rules to fight fraud

Draft regulations issued Monday would overhaul the prescription drug program and could save up to $1.3 billion over five years.

7 Jan 2014

Understanding long-term clinical stability in hemophilia patients living with HIV

People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

12 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

AAAS Honors Two Tufts University faculty members as Fellows

Two faculty members at Tufts University have been elected Fellows of the American Association for the Advancement of Science (AAAS), an honor bestowed upon AAAS members by their peers. John M. Coffin and planetary scientist Samuel P. Kounaves are among 388 new Fellows recognized by AAAS based on their distinguished efforts to advance science or its applications.

4 Dec 2013

HIV patients face higher risk of virologic failure than previously thought

People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold, according to a study by Claudie Laprise at the University of Montreal's Department of Social and Preventative Medicine.

26 Nov 2013

Younger people with HIV feel more isolated and stressed than older people

Case Western Reserve University researchers were surprised to learn that people younger than 50 years old with HIV feel more isolated and stressed than older people with the disease. They expected their study to reveal just the opposite.

21 Nov 2013

Reengineered protein may lead to safer, more effective retroviral gene therapy

A fusion protein engineered by researchers at KU Leuven combining proteins active in HIV and Moloney murine leukaemia virus (MLV) replication may lead to safer, more effective retroviral gene therapy.

16 Nov 2013

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.

4 Nov 2013

Full and early treatment may cure babies with HIV

A report published in The New England Journal of Medicine provides confirmation of what researchers say is the first case of HIV remission in a child born with the virus.

24 Oct 2013

Intervention of ID physician can reduce medication errors in hospitalized HIV patients

When patients with HIV are hospitalized for other conditions, such as a heart problem, surgery or complications of diabetes, mistakes are often made involving their complicated anti-retroviral therapy (ART) regimens.

5 Oct 2013

Cambridge Consultants helps MSF’s efforts to widen access to HIV viral load tests

Cambridge Consultants is working with Médecins Sans Frontières (MSF) to help support moves to expand access to vital diagnostic tests, which paves the way for better treatment of HIV in some of the world’s least-developed countries.

3 Oct 2013

New intravaginal ring delivers drug effectively, guards against HIV for 1 month

It's often said that the HIV/AIDS epidemic has a woman's face. The proportion of women infected with HIV has been on the rise for a decade; in sub-Saharan Africa, women constitute 60 percent of people living with disease. While preventative drugs exist, they have often proven ineffective, especially in light of financial and cultural barriers in developing nations.

28 Sep 2013

Study: Ciclopirox drug completely eradicates infectious HIV from cell cultures

The topical anti-fungal drug Ciclopirox causes HIV-infected cells to commit suicide by jamming up the cells' powerhouse, the mitochondria—according to a study by researchers at Rutgers New Jersey Medical School. And unlike current anti-HIV drugs, Ciclopirox completely eradicates infectious HIV from cell cultures, with no rebound of virus when the drug is stopped.

24 Sep 2013